Condition: Pharmacokinetic · Olverembatinib · Sponsor: Ascentage Pharma Group Inc.
This is a non-randomized, open-label, parallel, single-dose study to evaluate the pharmacokinetic profile of olverembatinib in participants with normal or impaired liver function.
This description comes directly from the study's public registry record.
Yifan Zhai, M.D., Ph.D. · 18998334688 · yzhai@ascentagepharma.com
Xiang Xu, M.D. · Xiang.Xu@ascentage.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Suzhou Medical University | Suzhou, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07282093